Reverse prospecting: detect the need before you sell

In B2B cold outreach, the average reply rate fell to 3.43% in 2026 (Instantly benchmark). The problem isn’t the copywriting; it’s the timing. Almost none of the prospects you contact are actually buying when your email lands.

Reverse prospecting flips that logic. Instead of pushing a message to a cold list, it first detects a public buying signal, then reaches out to a buyer who is already in decision mode. The reply rate climbs from 2 to 3% to 10 to 15%, because you’re talking to someone who already has a need.

This article defines the method, explains why getting there first changes the outcome, lists the signals that make it possible, walks through the five steps, and spells out who it works for.

What is reverse prospecting?

Reverse prospecting is a method that flips the question a sales rep starts with. It doesn’t ask “Who can I sell to?” but “Who already needs what I sell?” You monitor the public events that reveal buying intent, then contact the organization at the exact moment it’s making a decision. Agify built its MedTech method on this principle.

It’s neither inbound nor standard cold outreach. It’s a third way. When a hospital needs new equipment, it doesn’t wait for a sales rep’s email: it publishes a tender, renews an authorization with the ARS (regional health agency), appoints a new purchasing manager. These actions are public, and they say something specific: this facility is making a purchasing decision in an identifiable category.

The shift in posture is complete. When you contact someone because they just sent out a signal in your category, you’re no longer a cold caller. You’re someone who knew. The prospect doesn’t wonder why you’re calling; they wonder how you can help.

Why does being first on a buying signal change the conversion rate?

Being first to reach a buyer in decision mode is a structural advantage, not luck. According to Forrester, the seller who engages early and helps shape the buying vision before competitors do wins the deal more than 74% of the time. Reverse prospecting makes that early engagement systematic: it detects the signal as the need is taking shape, before the criteria are locked.

Forrester’s analysis (Mark Lindwall, 2014) puts it plainly in its research on first-mover advantage (original source no longer available): whoever helps the buyer build their vision of the solution, before competitors arrive, gains a lead the rest of the cycle never closes. In the hospital market, that means stepping in before the specifications are written, which is where a tender is won or lost, upstream of its publication.

What’s left is figuring out which signals announce a purchase in your specific market. That’s exactly what we frame during a prospecting scoping call: translating your product catalog into concrete signals to monitor.

Which public buying signals make reverse prospecting possible?

Six public sources hold the most reliable buying signals in the French hospital market. The BOAMP (France’s official public procurement bulletin) publishes tenders, the ARS publishes equipment authorizations, the HAS (France’s National Authority for Health) publishes certification deadlines, Hospimedia reports decision-maker appointments, the BODACC (France’s official bulletin of company announcements) records governance changes, and the PMSI tracks activity by facility. None of these sources is covered by Sales Navigator, Apollo, or ZoomInfo, including Sales Navigator’s Buyer Intent, which reads LinkedIn activity but not public health registries.

None of these signals means much on its own. It’s cross-referencing them on the same facility, identified by its FINESS code (France’s national registry of healthcare facilities), that turns a weak clue into a dated buying window. That’s the heart of it: buying intent doesn’t live on LinkedIn but in these public registries. It’s also what makes the method hard to copy: these registries require expert knowledge of the French healthcare market, not just a database export. And it’s why buying a B2B healthcare database means buying an asset that’s already dead: it freezes a snapshot, while the signal is a stream. An HAS certification nearing expiration only becomes a usable signal once it’s tied to the decision-maker and the facility’s purchasing calendar.

How do you apply reverse prospecting in five steps?

Reverse prospecting runs in five steps: define the signals specific to your ideal customer profile (ICP), monitor the sources continuously, qualify and score each signal, write a contextual message, then hand off to sales only the leads who replied. The method doesn’t change the product; it changes the sales process.

1. Define the signals. A 90-minute workshop with the head of sales identifies the events that, in their specific context, point to a buyer with intent. The signal for an MRI manufacturer isn’t the same as for an operating room software vendor.
2. Monitor continuously. AI agents scan the configured sources around the clock. Any signal that matches the client’s ICP (facility type, geography, specialty) surfaces automatically.
3. Qualify and score. Each signal is prioritized based on ICP fit, whether the decision-maker is identified, and freshness. A signal’s useful life is short, on the order of 7 to 21 days.
4. Write a contextual message. The message cites the specific event: “I noticed your department published a tender for [category].” This isn’t mass mailing; it’s signal-driven context. How you phrase that opening line comes down to a specific technique, cold reading.
5. Hand off to sales. The rep only receives confirmed meetings or leads who replied. Their ratio of selling time to prospecting time flips.

Where reverse prospecting tells you when to reach out, a complementary method tells you with what: deliver a free sample of value instead of pitching a service.

That’s exactly what Agify automates on public health data sources: monitoring, scoring, and contextualization, so only the signals worth a human conversation make it through.

Which companies does reverse prospecting work for?

Reverse prospecting works when the sales cycle runs 3 to 24 months, the deal size tops €10,000, several decision-makers are involved, and the purchase depends on a regulatory or budget context. It isn’t a fit for B2C sales, low-ticket products, or markets without usable public signals. The quality of the method depends directly on the quality of the signals you choose.

The fit criteria are clear. A long cycle gives you time to capitalize on an intent signal. A high deal size justifies the cost of research. Having several stakeholders (clinician, buyer, IT department) makes public signals useful for finding the right contact on each front. A product whose adoption depends on an ARS, HAS, or budget constraint naturally lines up with these signals.

The limits are just as clear. A signal isn’t intent: a tender may be captive, effectively already awarded, or just a market study. Scoring and human contact remain essential. And the method isn’t mass surveillance: only the signals relevant to the ICP surface. This buying-signal logic is detailed in the guide to MedTech prospecting through public sources and illustrated by a case study on qualifying radiologists at scale.

Frequently asked questions

What’s the difference between reverse prospecting and inbound?

Inbound waits for the prospect to come to you through content or search. Reverse prospecting stays outbound: the rep goes to the prospect, but only after detecting a public buying signal. You keep the initiative, but you use it when the need is already active rather than at random from a cold list.

Is reverse prospecting a form of mass surveillance?

No. The method only uses official public sources (BOAMP, ARS, HAS, BODACC) and only surfaces the signals that match the defined ICP. It isn’t about monitoring individuals; it’s about reading events that the facilities themselves have already made public, such as a tender or an equipment authorization.

What reply rate can you realistically expect?

Standard B2B cold outreach tops out around 3% (Instantly benchmark 2026: 3.43%). When you contact a prospect on a recent buying signal, the reply rate Agify observes falls between 10 and 15%. The gap doesn’t come from a better message but from talking to a buyer who is already in decision mode.

Does reverse prospecting work outside healthcare?

Yes, anywhere public buying signals exist and the sales cycle is long enough to capitalize on them. Public procurement (construction, GovTech) and industrial certifications (ISO) generate this kind of signal. A tech recruiting firm, for example, reads funding rounds and job posting volumes to reactivate a dormant lead database outside healthcare. An accounting firm applies the same approach to new business formations, through accountant prospecting via the INPI and BODACC registries. In construction, an installer detects plumbing and heating projects through public tenders and building permits. A law firm, for its part, reads hires and appointments as a sign that a client will soon be looking for counsel, before it shows up on LinkedIn. Where no public source exposes intent, you need to supplement with segment-level personalization.

How long does a buying signal stay actionable?

Its useful life is short, typically 7 to 21 days depending on the type of signal. A recent equipment authorization or appointment quickly loses its value as a buying window. That’s why monitoring has to be continuous and the pipeline responsive: a six-month-old signal is a dead signal.

Conclusion

Reverse prospecting isn’t a copywriting trick; it’s a change in entry point. Three things to remember: you contact a prospect because they sent out a buying signal, not because they’re on a list; being first on that signal is a structural advantage, measured by Forrester at up to a 74% success rate; and the method only holds up if the signals are well chosen and the follow-up is fast. That’s also what sets it apart from the mass-sending AI SDR that fails: the signal, never the volume.

In the French hospital market, a French MedTech company specializing in medical imaging applied this logic to narrow its list down, in six weeks, to the European radiologists who were truly qualified. What mattered was never the number of radiologists scraped: the size of a prospect database predicts no sales; only the qualification rate that comes out of it tells you anything. What’s left is identifying the signals that matter in your market. Let’s spend 30 minutes together on which public sources reveal your buyers before your competitors see them.

---

Agify deploys autonomous AI prospecting agents within B2B sales teams, with a specialization in the French MedTech market and its public health and public procurement data sources.